Abstract
The role of histaminergic neurotransmission in the promotion of waking has been extensively studied in preclinical species. Appreciation for the role of histamine continues to expand with increasing understanding of the interaction of histamine within the broad network of neuromodulators that regulate sleep and wake. The effects of histamine on waking are transduced through the H1 and the H3 receptors in the central nervous system. Brain penetrant over-the-counter antihistamines comprised of antagonist actions at H1 receptors as well as varying degrees of antimuscarinic properties are marketed as sleep aids, based on their well-known daytime drowsiness side effects. The data supporting their use as sedatives, however, are not consistent. H3 receptors are presynaptic receptors that limit histamine release as well as that of monoamine neurotransmitters thought to participate in the maintenance of waking. In this review, we discuss the existing studies on various antihistamines and antagonists of the H1 receptor in the regulation of sleep in preclinical studies, normal subjects and in subjects with sleep disorders. In addition, we review the current data available on the use of ligands at H3 receptors for the modulation of sleep and wake.
Keywords: Histamine, antihistamines, sleep disorders, insomnia, excessive daytime sleepiness, EEG, histamine H1 receptor, histamine H3 receptor, wake-promoting agents
CNS & Neurological Disorders - Drug Targets
Title: Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders
Volume: 6 Issue: 1
Author(s): A. J. Barbier and M. J. Bradbury
Affiliation:
Keywords: Histamine, antihistamines, sleep disorders, insomnia, excessive daytime sleepiness, EEG, histamine H1 receptor, histamine H3 receptor, wake-promoting agents
Abstract: The role of histaminergic neurotransmission in the promotion of waking has been extensively studied in preclinical species. Appreciation for the role of histamine continues to expand with increasing understanding of the interaction of histamine within the broad network of neuromodulators that regulate sleep and wake. The effects of histamine on waking are transduced through the H1 and the H3 receptors in the central nervous system. Brain penetrant over-the-counter antihistamines comprised of antagonist actions at H1 receptors as well as varying degrees of antimuscarinic properties are marketed as sleep aids, based on their well-known daytime drowsiness side effects. The data supporting their use as sedatives, however, are not consistent. H3 receptors are presynaptic receptors that limit histamine release as well as that of monoamine neurotransmitters thought to participate in the maintenance of waking. In this review, we discuss the existing studies on various antihistamines and antagonists of the H1 receptor in the regulation of sleep in preclinical studies, normal subjects and in subjects with sleep disorders. In addition, we review the current data available on the use of ligands at H3 receptors for the modulation of sleep and wake.
Export Options
About this article
Cite this article as:
Barbier J. A. and Bradbury J. M., Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders, CNS & Neurological Disorders - Drug Targets 2007; 6 (1) . https://dx.doi.org/10.2174/187152707779940790
DOI https://dx.doi.org/10.2174/187152707779940790 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endovascular Repair of Thoracic Aortic Aneurysms
Recent Patents on Cardiovascular Drug Discovery Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
Current Alzheimer Research Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction
Current Alzheimer Research In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Current Therapeutic Options for Alzheimers Disease
Current Genomics Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability
Current Alzheimer Research Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets